Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Yahoo Finance29d
Novo Nordisk A/S (NVO): A Bull Case Theory
Novo Nordisk (NVO) remains a dominant force in diabetes and obesity treatments, yet the stock is currently trading below its fair value. Despite a recent decline following disappointing trial ...
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
New York, New York-- (Newsfile Corp. - March 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, ...
New York Post8d
Novo Nordisk slashing price of Wegovy to $499 a month to uninsured following rival’s move
Novo Nordisk said on Wednesday it would begin selling ... pharmacies had until the court makes its decision in the earlier case to stop selling compounded tirzepatide, but has not said whether ...
Yahoo Finance9d
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame ...
The Motley Fool29d
Why Novo Nordisk Stock Keeps Going Down
Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...
FiercePharma8d
In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
In making his ruling, Pittman wrote that "good cause exists for Novo Nordisk's intervention in this case under Federal Rule of Civil Procedure 24." The rule allows for intervention of a third ...